Activity Overview
COVID-19 continues to pose significant clinical challenges in primary care, particularly for immunocompromised patients and other high-risk populations who may not mount adequate immune responses to vaccination alone. Despite advances in vaccination and treatment strategies, critical gaps persist in protecting vulnerable patients from SARS-CoV-2 infection and its complications, necessitating updated approaches to risk stratification, prophylaxis, and individualized prevention strategies. This archived recording of a live, accredited symposium was featured at the 2026 Family Medicine Experience (FMX) in Nashville, Tennessee, where our expert faculty panel discusses the evolving landscape of pre-exposure (PrEP) and post-exposure prophylaxis (PEP) options, along with emerging clinical trial data relevant to primary care clinicians seeking to stay current with evidence-based prevention strategies tailored to patient-specific risk factors and disease severity.
This educational activity is an archive of the live virtual symposium held on October 20, 2026.
System requirements for this online activity are available here.
Target Audience
This educational activity is intended for primary care physicians (PCPs), infectious disease (ID) specialists, critical care physicians, emergency medicine physicians, hospitalists, nurse practitioners (NPs), physician assistants (PAs), nurses, and pharmacists involved in the treatment of COVID-19.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the burden and impact of COVID-19.
- Evaluate emerging clinical trial evidence informing the use of current and investigational therapies for the prevention of COVID-19.
- Develop individualized strategies for patients at risk of COVID-19 tailored to disease severity and patient-specific factors.
Charles P. Vega, MD, FAAFP
Clinical Professor
Department of Family Medicine
Assistant Dean, Culture and Community Education
UC Irvine School of Medicine
Santa Ana, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Exact Sciences, GSK.
William P. Hanage, PhD
Associate Professor of Epidemiology
Co-Director, Center of Communicable Disease Dynamics
Harvard T. H. Chan School of Public Health
Boston, MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Merck Vaccines, Shionogi.
Ruth Carrico, PhD, DNP, APRN, FNP-C, CIC, FSHEA, FNAP, FAAN
Gratis Professor
Division of Infectious Diseases
University of Louisville School of Medicine
Senior Consultant
Carrico & Ramirez, PLLC
Louisville, KY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Dynavax Technologies (ended June 2025), GSK, Moderna (ended January 2025), Pfizer, Sanofi, Valneva, VaxCare; Speakers Bureau: Pfizer.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians Education Resource®, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for a maximum of 1.0 contact hour (0.1 CEU) under UAN # 0661-0000-26-006-H05-P. This UAN # expires 02/19/2028.
Eligibility for credits requires full engagement with the enduring activity, completion of the post-activity assessment questions, completion and submission of the activity evaluation, NABP e-pid # and month/date of birth within 30 days of activity completion. No partial credits are given.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Shionogi Inc.